Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
Commentary|Podcasts|July 30, 2024
Bridging the Vaccination Gap: Insights on Global Immunization Challenges
Author(s)Maggie L. Shaw
On this episode of Managed Care Cast, we speak with Jeffery A. Goad, PharmD, MPH, 2024-2025 president of the National Foundation for Infectious Diseases, on the recent report from the World Health Organization and UNICEF on public immunization rates, with national and global health implications.
Advertisement
Advertisement
On this episode of Managed Care Cast, we speak with Jeffery A. Goad, PharmD, MPH, professor of pharmacy at the Chapman University School of Pharmacy in Irvine, California; a fellow of the American Society of Health-System Pharmacists; and 2024-2025 president of the National Foundation for Infectious Diseases.
Related to this article
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
The NPS index, ranging from –100 to +100, serves as a proxy for customers’ willingness to recommend products and services they themselves have used.
The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.
NCCN concordance won't ensure coverage; OAB risk tied to income; 91% offer bispecifics; ruxolitinib spend hits $49.6M; TALK SAFE Act aids telepsychiatry.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Advertisement
Advertisement